The combination of B6H12 (CD47 antibody) and dinutuximab (GD2 antibody) increases the phagocytosis of neuroblastoma cells by microglia significantly, substantially enhances antitumor responses and extends tumor-free survival in a syngeneic model in NSG mice. The gene discussed is CD47; the disease is neoplasm.